March 1, 2024 7:16am

As a new month begins, March and more Q4/FY23 earnings

Pre-open Indications: 2 Positive and 1 Negative Indications

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi provides the extenuating factors of share pricing.

 

Friday: The pre-open Dow futures are DOWN -0.11% or (-44 points), the S&P futures are DOWN -0.07% or (-3 points) as the Nasdaq futures are UP +0.05% or (+9 points)

Stock futures were mixed and lower on Friday

European markets are higher

Asia Pacific markets were higher with South Korea shut for holiday

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Thursday, the Dow closed up +47.37 points or +0.12%, the S&P closed UP +26.51 points +0.52% while the Nasdaq closed UP +144.18 points or +0.90%

 

Thursday’s night RegMed Investors (RMi) Closing Bell: “investor jitters ss volume on the Nasdaq ran higher compared with the same time Wednesday.” … https://www.regmedinvestors.com/articles/13351

 

Q1/24: February – 1 market holiday, 11 positive and 9 negative closes

  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive indications:

Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

AxoGen (AXGN) closed up +$0.23 with a positive +$0.44 or +4.17 as earnings’ approach on 3/14, Thursday.

Vericel (VCEL) closed down -$2.12 with a positive +$0.82 or +1.80% pre-open indication.

 

Negative Indications:

Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

BioLife Solutions (BLFS) closed down -$0.20 after rearnings release with a negative -$1.30 or -7.69% pre-open indication.

 

The BOTTOM LINE:

The cell and gene therapy sector equities dived again on Thursday after Wednesday decent following Tuesday positive close following Monday and last Friday’s positive sessions.

  • The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.

15 (of 35 covered companies) have reported … RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes … https://www.regmedinvestors.com/articles/13166

 

I reiterate, “Don't chase the cell and gene therapy sector.”

Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

<span style="font-family:&quot;rom Friday" s="" market:",serif'=""> 

From Thursday’s market:

  • The stock market rally got off to a solid start Thursday as investors initially cheered the PCE inflation report. The major indexes soon slashed gains, but then rebounded again. <IBD>
  • The Nasdaq is 4.8% above the 50-day line, not quite extended but very close to being so once again
  • The 10-year Treasury yield dipped 2 basis points to 4.25%, but leapt 29 basis points in February.
  • The Nasdaq is not extended while small caps are testing major resistance.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.